Guidelines Extend Thrombectomy Window to 24 Hours

“This will be perhaps a once in a lifetime situation where a study gets published [and] within 2 hours is incorporated into new guidelines.”

The DEFUSE 3 Trial and the DAWN trial, released in 2017, provide overwhelming evidence that treating patients up to 24 hours after ischemic stroke can be safe and effective. The results of these trials resulted in rapid guideline updates by the American Heart Association and the American Stroke Association. Click on the link below for details about the new guidelines.